Memo Therapeutics
An innovator in the field of antibody discovery and immune repertoire analysis.
| EUR | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 1 % | (8 %) | 4 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Memo Therapeutics is a biopharmaceutical company specializing in developing innovative treatments for complex diseases through its cutting-edge therapeutic platform. Based on their proprietary technology, Memo Therapeutics focuses on designing highly selective and effective treatments by targeting specific disease mechanisms at the molecular level.
The company's core platform utilizes advanced computational and experimental methods to identify and validate novel therapeutic targets. Memo Therapeutics aims to address unmet medical needs by creating precise and tailored therapies that can improve patient outcomes in challenging areas such as oncology, autoimmune diseases, and neurodegenerative disorders.
Memo Therapeutics' approach combines deep scientific expertise with a commitment to translating discoveries into actionable therapies. Their pipeline includes several promising candidates that are undergoing rigorous preclinical and clinical evaluations. By leveraging state-of-the-art technology and a multidisciplinary team, Memo Therapeutics strives to bring transformative medicines to market, ultimately enhancing the quality of life for patients worldwide.